212 related articles for article (PubMed ID: 37469246)
61. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.
Stares M; Ding TE; Stratton C; Thomson F; Baxter M; Cagney H; Cumming K; Swan A; Ross F; Barrie C; Maclennan K; Campbell S; Evans T; Tufail A; Harrow S; Lord H; Laird B; MacKean M; Phillips I
ESMO Open; 2022 Apr; 7(2):100445. PubMed ID: 35398717
[TBL] [Abstract][Full Text] [Related]
62. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.
Derman BA; Macklis JN; Azeem MS; Sayidine S; Basu S; Batus M; Esmail F; Borgia JA; Bonomi P; Fidler MJ
BMC Cancer; 2017 Feb; 17(1):141. PubMed ID: 28209123
[TBL] [Abstract][Full Text] [Related]
63. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
Velcheti V; Hu X; Piperdi B; Burke T
Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
[TBL] [Abstract][Full Text] [Related]
64. Systemic Immune-inflammation Index is the Best Prognostic Factor in Patients with Advanced Stage Adenocarcinoma of the Lung Treated with Pemetrexed.
Bilgetekin I; Basal FB
J Coll Physicians Surg Pak; 2020 Sep; 30(9):933-939. PubMed ID: 33036677
[TBL] [Abstract][Full Text] [Related]
65. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
66. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
[TBL] [Abstract][Full Text] [Related]
67. Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study.
Ogiwara T; Kawazoe H; Egami S; Hashimoto H; Saito Y; Sakiyama N; Ohe Y; Yamaguchi M; Furukawa T; Hara A; Hiraga Y; Jibiki A; Yokoyama Y; Suzuki S; Nakamura T
Front Oncol; 2021; 11():770268. PubMed ID: 34820333
[TBL] [Abstract][Full Text] [Related]
68. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
[TBL] [Abstract][Full Text] [Related]
69. Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer.
Liu ZL; Zeng TT; Zhou XJ; Ren YN; Zhang L; Zhang XX; Ding ZY
Int J Biol Markers; 2016 Dec; 31(4):e395-e401. PubMed ID: 27416842
[TBL] [Abstract][Full Text] [Related]
70. Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
Matsuzawa R; Morise M; Kinoshita F; Tanaka I; Koyama J; Kimura T; Kondoh Y; Tanaka T; Shima K; Hase T; Wakahara K; Ishii M; Hashimoto N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3885-3893. PubMed ID: 36006483
[TBL] [Abstract][Full Text] [Related]
71. Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.
Takemoto S; Akagi K; Ono S; Tomono H; Honda N; Suyama T; Umeyama Y; Dotsu Y; Taniguchi H; Ogawara D; Senju H; Gyotoku H; Sugasaki N; Yamaguchi H; Nakatomi K; Fukuda M; Mukae H
Thorac Cancer; 2021 Sep; 12(17):2300-2306. PubMed ID: 34255933
[TBL] [Abstract][Full Text] [Related]
72. Tumor-infiltrating neutrophils and peripheral neutrophil-to-lymphocyte ratio conversely predicted the prognosis of patients with non-small cell lung cancer.
Yang R; Wang X; Ma C; Zhang Z; Liu N; Ma X; Zhang Y; Wang X; Liu Y
Cell Immunol; 2022 Sep; 379():104588. PubMed ID: 35961201
[TBL] [Abstract][Full Text] [Related]
73. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
74. Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
Öjlert ÅK; Nebdal D; Lund-Iversen M; Åstrøm Ellefsen R; Brustugun OT; Gran JM; Halvorsen AR; Helland Å
Acta Oncol; 2021 Feb; 60(2):149-156. PubMed ID: 33356733
[TBL] [Abstract][Full Text] [Related]
75. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
76. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
Zhang L; Wang Z; Fang J; Yu Q; Han B; Cang S; Chen G; Mei X; Yang Z; Stefaniak V; Lin Y; Wang S; Zhang W; Sun L; Yang Y
Lung Cancer; 2022 Sep; 171():56-60. PubMed ID: 35917647
[TBL] [Abstract][Full Text] [Related]
77. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
78. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
79. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
Choi MK; Hong JY; Chang W; Kim M; Kim S; Jung HA; Lee SJ; Park S; Chung MP; Sun JM; Park K; Ahn MJ; Ahn JS
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1217-25. PubMed ID: 24696125
[TBL] [Abstract][Full Text] [Related]
80. Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
Seto T; Azuma K; Yamanaka T; Sugawara S; Yoshioka H; Wakuda K; Atagi S; Iwamoto Y; Hayashi H; Okamoto I; Saka H; Mitsuoka S; Fujimoto D; Nishino K; Horiike A; Daga H; Sone T; Yamamoto N; Nakagawa K; Nakanishi Y
J Clin Oncol; 2020 Mar; 38(8):793-803. PubMed ID: 31880966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
